Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has been highlighted at NVIDIA's GTC artificial intelligence conference and accepted into the NVIDIA Connect program. The conference, attended by over 25,000 participants in San Jose, featured Stereotaxis' surgical robots during NVIDIA's VP of Healthcare and Life Sciences' special address.

Stereotaxis' robotic technologies have been utilized in over 150,000 patient treatments across more than 100 leading hospitals globally. The company is now focusing on digital solutions incorporating artificial intelligence, robotic automation, data integration, and decision support capabilities to enhance its robotic systems and operating room environment.

Through the NVIDIA Connect program membership, Stereotaxis gains access to NVIDIA's software development resources, frameworks, and development kits to support its technological advancement initiatives.

Positive

• Recognition and support from major tech company NVIDIA enhances credibility and technological capabilities
• Established market presence with over 150,000 patients treated across 100+ hospitals globally
• Strategic expansion into AI and automation technologies positions company for future growth

Negative

• None.

Insights

Financial Analyst

Stereotaxis's inclusion in NVIDIA's Connect program represents a strategic technology partnership that could accelerate the company's AI integration roadmap. While this announcement doesn't have immediate revenue implications, it provides Stereotaxis with access to NVIDIA's development resources and expertise - potentially reducing R&D costs and shortening time-to-market for AI-enhanced robotics solutions.

The company appears to be entering a new phase in its growth strategy, pivoting from hardware innovation toward intelligent software solutions. This digital transformation approach makes strategic sense for a medical robotics company with established hardware deployment (over 150,000 patients treated across 100+ hospitals globally).

For a company with a modest $178 million market capitalization, securing development support from a technology leader like NVIDIA is particularly valuable. It provides Stereotaxis with advanced AI capabilities without requiring massive internal investment. This partnership could potentially accelerate Stereotaxis's competitive positioning in the growing robotic surgery market, where intelligence-augmented solutions represent the next frontier of differentiation.

The partnership also provides valuable industry validation of Stereotaxis's technology direction, which may help with hospital adoption decisions and investor confidence. However, being highlighted at a conference and joining a developer program won't directly impact near-term financials, making this a modestly positive but primarily strategic development.

ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted Stereotaxis’ technology at NVIDIA GTC and has accepted Stereotaxis into the NVIDIA Connect program.

NVIDIA GTC (GPU Technology Conference) is a global artificial intelligence (AI) conference that brings together engineers, researchers, and inventors working to pioneer applications for AI. This year’s conference has brought together over 25,000 attendees in San Jose this week. At a special address by NVIDIA’s Vice President of Healthcare and Life Sciences, NVIDIA highlighted Stereotaxis’ surgical robots and the efforts to incorporate AI into robotics heralding a new chapter in medical progress. NVIDIA also recently accepted Stereotaxis into its NVIDIA Connect program, which supports member companies with NVIDIA’s software development resources, industry-leading frameworks and software development kits.

Stereotaxis’ robotic technologies are at the forefront of efforts to advance robotics in minimally-invasive endovascular surgeries. Its robots have already been used by physicians at over 100 leading hospitals globally to treat over 150,000 patients. As Stereotaxis nears completion of its initial wave of core innovations in robotics and interventional devices, it has set its sights on the next phase of technological progress. This includes a pronounced focus on digital solutions that enhance its robotic systems and the operating room environment with artificial intelligence, robotic automation, data integration and decision support capabilities. Stereotaxis has already begun meaningful investments in these efforts.

“We greatly appreciate the support of NVIDIA in our efforts to pioneer endovascular robotics and take the technology to new incredible heights,” said David Fischel, Stereotaxis Chairman & CEO. “The combination of robotics’ mechanistic benefits – precision, safety, stability – with the promise of AI innovations will dramatically transform what is possible in treating patients. We are excited for the path ahead of us.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

How many patients have been treated using Stereotaxis (STXS) robotic technology?

Stereotaxis' robotic technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

What benefits does the NVIDIA Connect program provide to Stereotaxis (STXS)?

The program provides Stereotaxis access to NVIDIA's software development resources, industry-leading frameworks, and software development kits.

What are Stereotaxis' (STXS) next technological development plans?

The company is focusing on digital solutions incorporating AI, robotic automation, data integration, and decision support capabilities to enhance its robotic systems.

How many hospitals currently use Stereotaxis (STXS) robotic technology?

Stereotaxis' robots are currently used by physicians at over 100 leading hospitals globally.